$RLFTF DD (opinion) by IlkaS on Yh0 - Hello all,
I haven't posted in a while but thought I would post on a recurring theme in the last two days : the supposed share dilution to be voted on at the June AGM.
That dilution is ALREADY PRICED INTO the current share price of RLF. It is related to the APR purchase. Here is the text from 4th May 2021 Press Release :
According to the Term Sheet, the APR shareholders will receive from Relief at the closing of a signed
transaction, CHF 22 million in cash, plus additional cash relating to APR’s working capital position at time of
close, and CHF 50 million payable in Relief common registered shares. The APR shareholders are also eligible
to receive additional contingent payments in the form of a combinatio
Immediately following that Press Release our share price dropped 17% in 3 days (3.92%, 8.12%, 5.56%). That was the pricing in of that dilution.
So there is nothing to worry about.
And a lot to look forward to : today Ram has added a Chief Operations Officer. This is almost certainly linked to NRx Pharmaceuticals' statement about filing for the EUA by Monday. When you add APR, Advita Lifescience, the EU Pharmaceuticals and everything we are involved in, I personally absolutely love this appointment because it confirms our management know what it takes to get to the next step and is not hesitating doing it.
For me it is all looking good : I topped up on an almost daily basis when we were in the 0.17 - 0.18, like many on here who were able to at the time, and it is all packed away in the safe now. Yes, every single one of us were looking for the COVID play, but when you are small everything takes longer, regardless of how good your product may be, I know that from experience. But I would remind anyone doubting of three critical points :
1. ARDS, Sarcoidosis, Severe Asthma, and more, are all in play for us. That, eventually, is an even bigger play than COVID.
2. COVID is still a play until mid-2022.
3. Last but not least, look at all the institutional investors who have kept adding to their millions of shares since February. Even Credit Suisse - they sold some for liquidity after the Archegos disaster, and then a few weeks later bought close to ten times what they sold post Archegos.
So, two words - DON'T SELL !
And if you are still hesitating, visit this board every day - there is fantastic due diligence by so many on here, all by people who own the shares.
It's all good.
Have a good weekend all.
Ciao.
Ilka
I haven't posted in a while but thought I would post on a recurring theme in the last two days : the supposed share dilution to be voted on at the June AGM.
That dilution is ALREADY PRICED INTO the current share price of RLF. It is related to the APR purchase. Here is the text from 4th May 2021 Press Release :
According to the Term Sheet, the APR shareholders will receive from Relief at the closing of a signed
transaction, CHF 22 million in cash, plus additional cash relating to APR’s working capital position at time of
close, and CHF 50 million payable in Relief common registered shares. The APR shareholders are also eligible
to receive additional contingent payments in the form of a combinatio
Immediately following that Press Release our share price dropped 17% in 3 days (3.92%, 8.12%, 5.56%). That was the pricing in of that dilution.
So there is nothing to worry about.
And a lot to look forward to : today Ram has added a Chief Operations Officer. This is almost certainly linked to NRx Pharmaceuticals' statement about filing for the EUA by Monday. When you add APR, Advita Lifescience, the EU Pharmaceuticals and everything we are involved in, I personally absolutely love this appointment because it confirms our management know what it takes to get to the next step and is not hesitating doing it.
For me it is all looking good : I topped up on an almost daily basis when we were in the 0.17 - 0.18, like many on here who were able to at the time, and it is all packed away in the safe now. Yes, every single one of us were looking for the COVID play, but when you are small everything takes longer, regardless of how good your product may be, I know that from experience. But I would remind anyone doubting of three critical points :
1. ARDS, Sarcoidosis, Severe Asthma, and more, are all in play for us. That, eventually, is an even bigger play than COVID.
2. COVID is still a play until mid-2022.
3. Last but not least, look at all the institutional investors who have kept adding to their millions of shares since February. Even Credit Suisse - they sold some for liquidity after the Archegos disaster, and then a few weeks later bought close to ten times what they sold post Archegos.
So, two words - DON'T SELL !
And if you are still hesitating, visit this board every day - there is fantastic due diligence by so many on here, all by people who own the shares.
It's all good.
Have a good weekend all.
Ciao.
Ilka
1
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
